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Citral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and anti-
inflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a 
mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 
12): normal control group (NC) receiving a normal diet; high-fat emulsion group (HF) receiving high 
fat diet for four weeks; positive control group (C+) receiving HF diet for four weeks and then shifted to 
normal diet with IP-administered silymarin (80 mg/kg) for four weeks; sham group receiving HF diet 
for four weeks and then shifted to normal diet for four weeks; and EC1, EC2, and EC3 groups receiving 
HF diet for four weeks and then shifted to normal diet with IP-administered citral doses of 5, 10, and 
20 mg/kg, respectively. HF diet resulted in steatohepatitis with impaired lipid profile, high glucose levels 
and insulin resistance, impaired liver enzymes, antioxidants, adiponectin and leptin levels, decreased 
PPARα level, and fibrosis in the liver tissue. Upon treatment with citral, improvement in condition was 
observed in a dose-dependent manner—both at histological level and in the serum of treated animals. 
and the PPARα level was also increased.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the 
most important cause of chronic liver diseases (Videla et 
al., 2006). It is considered as the hepatic manifestation 
of metabolic syndrome (MS) (Lonardo et al., 2005, 
Krawczyk, Bonfrate, Portincasa, 2010). NAFLD is 
defined as accumulation of fat in the liver in the absence of 
excessive drinking of alcohol. The condition can progress 
from simple non-alcoholic steatosis (NAS) to non-
alcoholic steatohepatitis (NASH), and finally to hepatic 
fibrosis (Ahmed, 2015).
NAFLD is associated with metabolic risk factors 
such as obesity, diabetes mellitus, dyslipidemia, and 
oxidative stress (Krawczyk, Bonfrate, and Portincasa, 
2010). In order to study this condition and find potential 
treatments, animal models of steatohepatitis, insulin 
resistance, and obesity are useful (Koteish, Diehl, 2002). 
Oxidative stress occurs when the balance between 
Reactive Oxygen Species (ROS) and antioxidant 
molecules is impaired (Seren et al., 2008). Hepatic 
overloading of FFA may cause oxidative stress (Chew, 
Park, 2004). ROS-induced oxidative stress is observed in 
obesity and NAFLD, in both humans and rodents (Aubert 
et al., 2011). In fact, ROS may act on lipid peroxidation 
of polyunsaturated fatty acids, resulting in the production 
of malondialdehyde (MDA). MDA has long-term adverse 
effects on liver cells (Day, 2006). In liver steatosis, 
increased levels of cytokines—such as tumor necrosis 
factor-alpha (TNF-α)—are also observed (Zahran et al., 
2013). Finally, histological changes indicative of this 
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disorder occur in the perivenular regions of the liver 
parenchyma (Guicciardi et al., 2013).
Previous studies have shown that high caloric intake 
is an important factor frequently associated with NAFLD 
as well as other metabolic syndromes in humans. Hepatic 
steatosis may also develop when animals are fed ad 
libitum with a high-fat diet (Zou et al., 2006). In addition, 
Peroxisome Proliferator-Activated Receptor Alpha 
(PPARα) gets markedLy decreased over high-fat (HF) 
intake. PPARs are important ligand-activated transcription 
factors involved in the regulation of nutrient homeostasis 
(Feige et al., 2006) and expressed in a variety of tissues and 
organs, such as liver, kidney, heart, and muscle. They can 
regulate energy homeostasis, stimulate gluconeogenesis 
and fatty acid catabolism, and are involved in the control of 
lipoprotein assembly (Rakhshandehroo et al., 2010). Some 
evidences showed that PPARα is an important regulator of 
hepatic (mitochondrial and peroxisomal) beta-oxidation. 
PPARα is markedLy decreased by HF intake (Souza-
Mello, 2015) and, thus, could be involved in controlling 
the disease state.
Citral, formed by enantiomers neral (cis) and geranial 
(trans), is the major aliphatic aldehyde monoterpene of 
Lippia alba and Cymbopogon citratus. It is found in all 
citrus species. Lemongrass (Cymbopogon citratus), an 
evergreen plant growing in Asia, is an important source 
of this oil. Citral has antimicrobial, anti-inflammatory 
(Martins et al., 2017) as well as anti-hyperlidemic effects 
(Najafian et al., 2011). It is obtained at low cost and 
shows no particular toxicity at low doses (Dieter et al., 
1993). As a retinaldehyde dehydrogeanse inhibitor, it is 
demonstrated that citral administration can significantly 
lower body weight gain and abdominal fat mass in rats on 
a high-energy diet. while decreasing serum insulin levels 
and improves glucose tolerance (Modak, Mukhopadhaya, 
2011). Retinaldehyde can activate PPAR receptors, leading 
to an increase in serum adiponectin levels, which has 
beneficial effects in regulating both the liver and muscle 
metabolism (Yang et al., 2005). Overall, based on these 
previous studies, citral seems to be a good candidate for 
improving or decreasing fatty liver injuries. We have, thus, 
investigated the effect of citral compounds on biochemical, 
histological indicators, and PPARα gene expression, 
induced by high caloric diet in male NMRI mice.
MATERIAL AND METHODS 
Material
Citral was obtained from Sigma-Aldrich, St. 
Louis, MO, USA. Commercial kits were used for the 
measurement of high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol (LDL-C), 
total cholesterol, triglycerides (TG), glucose, alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), and alkaline amino transferase (ALP). These 
were purchased from the ZistChimi Chemical Company, 
Tehran, Iran. Serum adiponectin, leptin, and the insulin 
measurement kits were purchased from Yanaihara 
Institute Inc. Catalog No. YII-YK052-EX, JAPAN. 
The homeostasis model assessment (HOMA) formula 
was used as an insulin resistance index: HOMA = 
fasting serum insulin (mU/L) × fasting plasma glucose 
(mM)/22.5 (Barnea et al., 2006).
Preparation of fat emulsion
High-fat emulsion diet was prepared with the 
following components: Cholesterol (> 95% [CG] Sigma), 
Tween80, sucrose, sodium deoxycholate and propylene 
glycol (Sigma-Aldrich), total milk powder (Aptamil), 
multivitamin, and carbohydrates. The composition of this 
emulsion is shown in Table I. In this emulsion, total milk 
powder provided proteins. However, carbohydrates source 
was sucrose, fat was obtained by corn oil, and the diet was 
supplemented with a vitamin and mineral mixture. This 
emulsion was stored at 4 °C and then heated in a 42 °C 
water bath, and fully mixed before use.
Animals and treatment
Male NMRI mice (6 weeks old and 25-30 g) were 
supplied by Razi Vaccine and Serum Institute, Karaj, 
Iran. They were kept in cages in an animal’s room under 
TABLE I - Composition and caloric content of the high-fat 
emulsion diet
Components of high fat emulsion Amount
Corn oil(g) 178
Saccharose(g) 13.37
Total milk powder(g) 7.13/2
Cholestrol (g) 8.92
Sodium deoxycholate(g) 0.89
Tween 80 (g) 3.25
Propylene glycol(g) 2.78
Multi Vitamin 0.22
Cooking Salt(g) 0.89
Mineral mixture (g) 0.13
Distilled water (mL) 40.1
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standard conditions (temperature 22±1°C and a 12-h 
light–dark cycle). They were given ad libitum access to 
standard pellet and water.
After a week of adaption, the animals were weighed 
and divided into the following groups (n = 12):
•	 Normal control group (NC group) received normal 
diet.
•	 High-fat emulsion group (HF group) received high 
fat diet, which was composed of normal diet supple-
mented with additional high-fat emulsion (Table I) 
for four weeks (Zou et al., 2006).
•	 Positive control group (C+) received high-fat emul-
sion for four weeks and was then shifted to NC with 
silymarin (80 mg/kg) administered by intraperito-
neal injection(IP) for four weeks.
•	 Sham group received high-fat emulsion for four 
weeks and was then shifted to normal diet for four 
weeks.
•	 EC1 group received high-fat emulsion for four 
weeks and was then shifted to NC with citral 
(5 mg/kg), administered by intraperitoneal injection 
(IP) for four weeks.
•	 EC2 group received high-fat emulsion for four 
weeks and was then shifted to NC with citral 
(10 mg/kg), administered by intraperitoneal injec-
tion (IP) for four weeks.
•	 EC3 group received high-fat emulsion for four 
weeks and was then shifted to NC with citral 
(20 mg/kg), administered by intraperitoneal injec-
tion (IP) for four weeks.
•	 Protective group (PC) received high-fat emulsion 
and citral 20 mg/kg simultaneously for four weeks.
All NMRI mice were fed with standard rodent food 
and water. The model mice received high-fat emulsion via 
oral gavage every day for four weeks. The NC group was 
given equal volumes of saline via daily gavage (Zou et al., 
2006). At the end of the treatment with high-fat emulsion, 
animals from the HF group were selected randomLy. 
Their livers were removed under diethyl ether anesthesia. 
Histopathological examination was conducted on the liver 
tissue and fatty cell formation was confirmed. Treatment 
with citral and silymarin (test and positive control groups) 
continued according to the experimental protocol for four 
weeks by IP injection. During the experimental period, 
all animals were weighed every week. The experimental 
protocol was performed in accordance with the Guide 
for the Care and Use of Laboratory Animals (Institute 
of Laboratory Animal Resources, 1996). Moreover, the 
University’s Animal Ethics Committee approved the 
protocol.
Histological and biochemical assessment
At the end of the experiment, animals were made 
to fast (12 hours without food) and then weighed. NMRI 
mice were anesthetized by inhalation of diethyl ether. 
Terminal blood sample withdrawal from cardiac ventricles 
was conducted with the help of 2.5 mL syringes. Liver 
tissues were removed and fixed in a formalin buffer 
solution (10%) in order to do histological assessment. 
After embedding the tissues in paraffin, cross sections of 
5 µm were prepared according to the routine protocols. 
Liver sections were stained with hematoxylin and eosin 
(H&E) and Masson’s Trichrome (MT). The slides were 
examined by light microscopy. Liver tissue samples were 
also used to measure antioxidant enzyme activities and 
other biochemical parameters, such as hepatic SOD and 
malondialdehyde (MDA) activities. Tissue samples were 
removed, weighed, and then homogenized (1:3 w/v) 
in phosphate saline buffer (pH = 7.4). Homogenate 
samples were then sonicated for 1.5 minutes and bursts 
for 30 seconds. All the procedures were performed at 
0-4 °C. Homogenate samples were finally centrifuged at 
22,000g for 17 minutes at 4 °C in a microcentrifuge. The 
supernatant was frozen at –40 °C till the time of assay. 
Visceral white adipose tissue was taken and stored at 
-70 °C for molecular analysis. The serum levels of HDL-C, 
LDL-C, TG (Marklund, Marklund, 1974; Asadi et al., 
2008), ALP, AST, and ALT, Ferric Reducing Antioxidant 
Power (FRAP), catalase, total protein, insulin, glucose 
TNF-α, adiponectin, and leptin were measured using 
commercial kits.
RNA isolation and cDNA synthesis
Total RNA was isolated from whole mice liver 
tissue by using a commercial RNA isolation kit (Roche 
Diagnostics GmbH Roche Applied Science 68298 
Mannheim, Germany). The cells were suspended in 
200 μL PBS, to which 400μl Lysis/Binding Buffer was 
added and mixed for 15 seconds. After transferring it 
to a high pure filter tube, centrifugation was done for 
15 seconds at 8,000 × g. Flowthrough was discarded 
and 100 μL DNase was added, incubating the mixture 
for 15 minutes at 25 °C. Washing buffer was used twice, 
followed by centrifugation, and RNA was eluted by 
100 μL Elution Buffer. The purified RNA can be used 
directly in RT-PCR or stored at -80°C for later analysis.
The primer sequences for PPAR α and HPRT (used 
as housekeeping gene) were obtained from Yekta tajhize 
Azma website. Specific primers were designed by the 
primer express program (Table II).
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Statistical analysis
The data was analyzed using SPSS statistical 
software and mean±SEM (standard error of mean), 
followed by Turkey’s post hoc test. P < 0.05 was set as a 
statistical significance.
RESULTS
Body weight
After four weeks, weights of the mice of different 
groups were significantly different, as compared with the 
control group (Table III). Removing high fat diet from Sham 
group for four weeks caused a decrease in body weight, 
as compared with the HF group (P < 0.001). Between 
the experimental groups, the body weight of EC2 (citral 
10 mg/kg), EC3 (citral 20mg/kg), and PC (protective group; 
citral 20 mg/kg, with high fat diet simultaneously) were 
significantly reduced in comparison to HF (P < 0.001). 
Furthermore, body weight in EC3 group was significantly 
lower than EC1 and EC2 groups (P < 0.001). These results 
demonstrated that the highest used dose of citral was more 
efficient in body weight reduction in the HF group.
Biochemical parameters
Measured biochemical parameters including 
cholesterol, glucose, liver enzymes, and insulin are shown 
in Table IV. The serum levels of cholesterol, TG, LDL, 
VLDL, total lipid, phospholipid, and liver enzymes in the 
HF group showed a significant increase in comparison 
with the control group (P < 0.001). On the other hand, the 
levels of cholesterol and TG in treated groups significantly 
decreased, as compared with the HF and Sham groups 
(P < 0.001). Phospholipid levels decreased in EC3 and 
PC groups, as compared with the HF and Sham groups 
(P < 0.001).
The HDL-C levels were markedLy reduced in the 
HF group and increased in EC3 group, and to a lesser 
extent in the Silymarin group (Table IV). The serum 
levels of LDL-C in HF group significantly increased, as 
compared with the control group. However, in EC3 group, 
significant reduction was observed, as compared with HF 
and Sham groups (P < 0.001).
The levels of the hepatic enzymes ALP, AST, and 
ALT were increased in HF group, as compared with 
the control group (P < 0.001). Treatment with citral 
(20 mg/kg) caused a significant decrease in all liver enzyme 
levels, as compared with the HF and Sham group (P < 0.001). 
A similar result was seen for Silymarin (Table IV). Glucose, 
serum insulin levels, and insulin resistance significantly 
increased in the HF group, as compared with the control 
group (P < 0.001). Citral (20 mg/kg) administration 
affected all these factors and caused a significant decrease, 
in comparison to HF and Sham groups. This phenomenon 
was similar to that of Silymarin (Table IV).
TNF-α levels markedLy increased in the HF 
group, as compared with the Control group. However, it 
significantly decreased in the citral treated groups (both 
EC3 & PC), as compared with the HF and Sham groups 
(P < 0.001) as well as the C+ group. The liver enzymes 
superoxide dismutase (SOD), malonyledialdehyde 
(MDA), and catalase were affected by high fat emulsion 
in the HF group, as compared with the Control group 
(Table IV). The serum levels of SOD and catalase showed 
a significant increase in EC3, PC, and C+ groups, as 
compared with the HF and Sham groups, while MDA 
levels significantly decreased (Table IV).
TABLE II - Sequences of probe and oligonucleotides used in 
real-time PCR analysis
 
Gene Sequence
PPAR α 
(Forward)
5’GGGGAACTTAGAGGAGAGCCAAG 3’
PPAR α 
(Reverse)
5’CGCTAAGCTGTGATGACAACG3’
HPRT 
(Forward)
5’TCAGACTGAAGAGCTACTGTAATGATCAG3’
HPRT 
(Reverse)
5’TCAACAATCAAGACATTCTTTCCAG3’
TABLE III - Comparison of body weights at the end of the experiment
Group NC HF C+ Sham Ec1 Ec2 Ec3 Pc
Initial weight 27±1 24±0.5 25±0.7 27±0.4 26±0.3 25.3±0.3 25.6±0.4 26.8±0.3
After 4 weeks 40.5±0.4 49.5±0.3 
***
37±0.6 
$$$
42.6±1 
$$$
37.6±0.6 
###$$$
37±0.7 
$$$ ###
30.9±0.9 
$$$ ###
38.4±0.5 
$$$ ##
*** p<0.001 compared with control, $$$ p<0.001 compared with HF, ##<0.01 compared with sham, ### p<0.001 compared with 
Sham
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TABLE IV - Effect of citral on biochemical indices and antioxidant enzymes in mice treated with high fat emulsion. Data are expressed 
as mean±SEM. *** p<0.001compared with NC (Normal control),$$$p<0.001 compared with HF, ®®® p<0.001 compared with 
sham, $$ p<0.01 compared with HF, ®® p<0.01 compared with sham, $ p<0.05 compared with HF(high fat), ® p<0.05 compared 
with sham.
Group NC HF C+ Sham EC1 EC2 EC3 PC
Parameters
Cholesterol (mg/dL) 116.5±2.8 230.5±2 
***
90.67±1 212±2 
$$$
198.5±0.3 
$$$®®®
197.5±3.9 
$$$®®®
160.3±0.8 
$$$®®®
161.98±98 
$$$®®®
TG (mg/dL) 70.86±2 131.4±5 
***
68±0.5 122±1 
$$$
110.6±0.4 
$$$®®®
107.9±0.4 
$$$®®®
103.4±1 
$$$®®®
110±1 
$$$®®®
HDL (mg/dL) 74.94±3 59.41±2 
***
49.67±0.2 61.2±0.6 ------------ ----------- 73.1±0.8 
$$$®®®
63±0.5
LDL (mg/dL) 31.19±3 126.8±3 
***
30.7±1.2 129.2±2.9 -------------- ----------- 59.54±1.5 74.8±1.5
VLDL (mg/dL) 13.9±0.4 32.7±3 
***
13.1±0.2 24.8±1.4 23.07±0.5 23.7±0.5 25.3±0.5 22.26±0.3
Total lipid (mg/dL) 249.1±3 446±19 
***
213.5±0.7 446.9±13 ------------- ----------- 360.29±3 
^^^
358±3
Phospho lipid (mg/dL) 182.8±2 250.9±5 
***
158.6±0.8 
$$$
263±3 
$$$
------------- ------------- 205±0.5 
$$$
209±3 
$$$
AST (u/L) 64.34±0.7 93.41±1.5 
***
66.8±0.7 
$$
81±0.8 
$$$
87.7±3 84.3±1 69.6±1 
$$$ ®®®
79.7±1 
$$$
ALT (u/L) 79±0.7 106±3.3 
***
70±2 
$$$
90.5±6 96.5±0.7 93.5±3 66.9±1 
$$$®®®
90.4±0.5 
ALP (u/L) 140.6±0.8 162±2.5 
***
133.5±1 
$$
150±1 ------------- ------------ 139±0.3 
$$$®®®
157±8 
Adiponectin (ng/mL) 4.9±0.1 2.2±0.2 
***
4.5±0.1 2.6±0.1 2.09±0.09 2.93±0.9 3.7±0.1 
$$$®®®
2.6±0.06 
Leptin ( ng/mL) 10.3±0.3 19.3±1 
***
14.08±0.7 13.2±0.1 ------------ ------------ 16.6±0.4 
$$$®®®
16.05±0.2 
$$$®®®
Fbs (mg/dL) 99.2±1 127.2±1 
***
96.2±0.4 125.3±1 ---------------- ------------ 109.4±4 
$$$®®®
126±1
Insulin (ng/mL) 0.45±0.05 2.01±0.07 
***
0.96±0.0 1.04±0.1 ---------------- ------------ 0.87±0.02 
$$$®®®
0.96±0.007 
HOMA 2.15±0.2 13.7±0.3 
***
4.08±0.03 5.7±0.4 -------------- ---------- 2.9 ±0.1 
®®® $$$
4.3±007 
$$$
TNF-α (pg/mL) 74.3±3 96.04±1 
***
61±00 88.3±1 -------------- ----------- 65.8±0.4 
$$$®®®
75.8±2 
$$$®®®
MDA (U/mg-p) 4.08±0.1 6.5±0.07 
***
5.1±0.08 6.09±0.05 5.8±0.1 5.1±0.06 
$$$ ®®®
4.9±0.2 
$$$ ®®®
5.2±0.09 $ 
 ®® 
SOD (U/mg-p) 19.8±0.5 14.02±0.5 
***
16.6±0.1 13.8±0.1 ------------ ----------- 17.3±0.2 
$$$®®®
15.3±0.1 
$®®
Catalase (U/mg-p) 53.6±0.1 40.1±0.8 
***
55.3±0.1 41.1±1.4 ------------ ----------- 49.6±0.6 
®®®$$$
46.1±1 
®® $
FRAP (U/mg-p) 19.7±0.2 14.3±0.2 
***
------------- 14.9±0.07 15.4±0.04 
$$$
15.3±0.09 
$$$
17.2±0.1 
$$$®®®
15.1±02 
$$
Tprotein (mg/dL) 2.6±0.1 4.7±0.1 
***
3.5±0.08 4.1±0.1 
$$$
3.6±0.09 
$$$
3.4±0.07 
$$$
2.9±0.04 
$$$®®®
3.9±0.1
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Ferric Reduction Antioxidant Power (FRAP) levels 
were reduced in the HF group, as compared with the 
Control group. However, it increased in all the treated 
groups, as compared with the HF group. The differences 
in FRAP levels between EC3 and Sham groups were 
remarkable (Table IV). Serum adiponectin levels 
decreased in the HF and Sham groups and significantly 
increased in C+ and EC3 groups. Treatment with high fat 
emulsion resulted in a significant increase of leptin levels 
in the HF group. The consumption of silymarin and citral 
(20mg/kg) could decrease leptin levels, as compared with 
the HF and Sham groups (Table IV).
Gene expression
Percentages of PPARα gene expression evaluated in 
liver tissue are showed in Figure 1. The highest percentage 
of increase in PPARα gene expression was observed in 
EC3 group, as compared with control (Figure 1). On the 
other hand, a significant increase (30±3%) in EC3 group 
was observed, as compared with the HF and Sham group 
(24±1%) (P < 0.001).
Histopathological Evaluation
Histological changes occurring in NAFLD can affect 
the liver parenchyma, as observed in liver samples stained 
with Hematoxyline & Eosine (Figure 2A, C, E, G, I, K, 
M, O) and Masson’s trichrome (Figure 2B, D, F, H, J, L, 
N, P). In the Control group, normal hepatic cells were 
observed after four weeks (Figure 2A & B). However, 
the livers of the HF group were found grossly larger, as 
compared with the NC group. Liver steatosis was showed 
as a change in liver fatty cells in this group (indicated with 
arrows in Figure 2). There was marked perivenular fibrosis 
in the HF group, which is observed in Masson’s trichrome 
staining (arrows in Figure 2D). Fibrosis is highlighted in 
blue by this stain.
In the group that received silymarin after high fat 
emulsion, steatosis was alleviated (Figure 2G & H). A 
similar condition to the control group was observed. In 
the liver sections of the Sham group, mild fibrosis was 
observed around the portal tract (Figure 2H).
In the groups treated with citral (5,10, and 
20 mg/kg), depending on the dose, fatty content change 
in hepatocytes was affected at accordingly different extent 
(Figure 2M). In the 20 mg/kg group, liver steatosis was 
no more observed.
DISCUSSION
In the current study, four weeks of treatment with 
high fat emulsion was used to induce NAFLD in NMRI 
mice. The histological changes occurring in NAFLD 
predominantly affected the liver parenchyma and fat 
changes were mostly macrovesicular in nature. At the end 
of this period, fat accumulation in the liver was clearly 
observed by hematoxylin and eosin (Figure 2C).
Masson’s trichorome staining showed fibrosis 
around the hepatic parenchyma (Figure 2D).
Animals were then treated with citral for four 
weeks. The effects of this compound were assessed using 
the following parameters: body weight, lipid profiles, 
antioxidant enzymes levels, serum levels of adiponectin 
and leptin, glucose and insulin levels, liver tissue histology, 
and PPARα gene expression in liver tissue. Silymarin, 
which consists of polyphenols and is derived from the 
milk thistle plant, was used as a positive control. This was 
because it is currently considered to have favorable effect 
in the treatment of NAFLD (Del Ben et al., 2017).
High fat emulsion leads to an increase in body 
weight in rodents when used for six weeks (Zou et al., 
2006). Our results were in accordance with this study 
(although with a difference in the period of treatment). 
Our study showed that HF emulsion caused a significant 
increase in the body weight of mice after four weeks, 
as compared with the Control group. The results of 
the experimental groups (compared with Sham group) 
showed that treatment with citral, especially citral at a 
20mg/kg, caused a reduction in body weight. This seems 
to have a better effect, as compared with silymarin. 
Similar findings have been reported in rodent models 
of diabetes (Najafian et al., 2011) and obesity (Modak, 
Mukhopadhaya, 2011), where citral is suggested to 
act via an anti-appetite effect or increase in energy 
expenditure.
FIGURE 1 - Comparison of PPAR α gene expression between 
HF, Sham and EC3 with control. ***p<0.001 compared with 
control.
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FIGURE 2 - Histopathological effects of citral on liver tissue in HF-fed mice (magnification:100). Liver tissue sections assessed by 
Hematoxyline & Eosin (H&E- A,C,E,G,I,K,M) and Masson’s trichorome (MT- B,D,F,H,J,L,N) perivenular fibrosis was observed 
in Masson’s trichrome , arrows in fig 2 D show the parts of the liver tissue that have been altered to blue color due to fibrosis. Fatty 
change in hepatocytes (HF) group was observed with Hematoxyline & Eosine, in Fig 2 C. The arrows show the fat cells in liver 
tissue. In other images of Hematoxyline & Eosine staining arrows show three different parts of liver tissue , which include central 
vein (CV), portal triad (PT) and hepatocyte cells (H). A: Hematoxyline & Eosin for control group; B: Masson’s trichorome for 
control group; C: Hematoxyline & Eosin for HF group; D: Masson’s trichorome for HF group; E: Hematoxyline & Eosin for Sh 
group; F: Masson’s trichorome for Sh group; G: Hematoxyline & Eosin for C+ (silymarin) group; H: Masson’s trichorome for 
C+ (silymarin) group; I: Hematoxyline & Eosin for EC1 ( citral 5 mg/kg) group; J: Masson’s trichorome for EC1 (citral 5 mg/kg) 
group; K: Hematoxyline & Eosin for EC2 (citral 10 mg/kg) group; L: Masson’s trichorome for EC2(citral 10 mg/kg) group; M: 
Hematoxyline & Eosin for EC3(citral 20 mg/kg) group; N: Masson’s trichorome for EC3(citral 20 mg/kg) group; O: Hematoxyline 
& Eosin for PC (protective) group; P: Masson’s trichorome for PC (protective) group. Abbreviation: CV(central vein), PT(portal 
triad) and H (hepatocyte cells). 
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Increasing levels of lipid profiles indices cholesterol, 
TG, LDL-C, total lipid, phospholipid, and reduction of 
HDL-C levels are observed in obesity (Asadi, Shahriari, 
Chahardah-Cheric, 2010). They are risk factors associated 
with oxidative stress that lead to hepatic metabolic disorder 
(Saravanan et al., 2014). The liver has an important role 
in lipid metabolism. Imbalance between production and 
consumption of lipids causes hepatic steatosis (Stanton 
et al., 2011).
The measurement of serum ALP, AST, and ALT 
provides an indication of liver function (Hall, Cash, 
2012). At the end of the experimental period, plasma 
levels of these parameters increased in the HF group, 
which were modulated by citral administration. At a high 
dose, the therapeutic effect may be exerted throughout the 
antioxidant activity (Yang et al., 2013). Previous studies 
have showed that high fat diet results in increased oxidative 
stress and reduces free radical scavenger enzymes, which 
finally cause cell damage (Sreekumar et al., 2002). 
Hepatic concentration of MDA enzyme (products of lipid 
proxidation) increases and the SOD activity is reduced 
(Zou et al., 2006). Antioxidant enzymes, like SOD and 
catalase, protect cells from damage with the help of 
breakdown free radicals. When SOD can break down 
anion superoxide (O2
-) into hydrogen peroxide (H2O2), 
catalase converts it immediately to water. The positive 
effects of citral administration (20mg/kg) on MDA, SOD, 
and catalase are in accordance with a previous study. This 
suggests lemongrass inhibition of free radical attacks on 
biomembrane (Ojo et al., 2006). Citral can inhibit the 
process of increase in ROS (Reactive Oxygen Species) 
and NO production. In this regard, citral compound may 
have a therapeutic effect on hepatic diseases through 
the inhibition of oxidative stress (Yang et al., 2013). 
Interestingly, silymarin, which attenuates liver fibrosis 
associated problems, has also been reported to act as an 
antioxidant (Del Ben et al., 2017).
Insulin resistance exacerbates the abnormalities in 
hepatic fat metabolism. With insulin resistance (as a strong 
predictor of NAFLD), the combination of increase in 
plasma concentrations of glucose and fatty acids promotes 
hepatic fatty acid synthesis and impairment of β-oxidation. 
This further leads to hepatic steatosis (Zammit, 2002). The 
finding of this study showed that feeding mice with high 
fat emulsion caused a significant increase in the serum 
levels of glucose, insulin, and index of insulin resistance 
(HOMA), in comparison with the control group. In fact, 
the reduction of insulin levels was accompanied with 
improved glucose tolerance. Previous reports showed 
that citral has an insulin-sensitizing and alpha-amylase 
inhibitory effect (Zammit, 2002; Najafian et al., 2011). 
Furthermore, reduction in TG and cholesterol after use of 
citral can be attributed to better utilization of glucose. This 
was reflected by a decrease in blood glucose and increased 
insulin levels and, therefore, depressed mobilization of fat 
(Lonardo et al., 2005).
Decreased levels of adiponectin in HF group, as 
compared with the Control group, were increased upon 
citral administration. In fact, adiponectin can prevent the 
accumulation of lipids by increasing the beta oxidation of 
free fatty acids in hepatocytes (Ma et al., 2002). On the 
other hand, both leptin and adiponectin play an important 
role in energy balance. Adiponectin can modulate 
glucose and fatty acid metabolism. Leptin is a mediator 
of energy balance, suppressing food intake, and thereby 
inducing weight loss (Klok, Jakobsdottir, Drent, 2007). 
Furthermore, hyperleptinemia can help hepatic statosis due 
to changes in the accumulation of hepatic fat (Chitturi et 
al., 2002). Changes in the levels of adipokines can improve 
insulin resistance, obesity, and fatty liver (Ghantous et 
al., 2015). Similar to other reports, the current study 
showed that high fat emulsion increased serum leptin 
and decreased adiponectin levels in animals (Barnea et 
al., 2006), and citral can affect both parameters. In the 
current study, overall comparison of citral and sylimarin 
on the above-discussed biochemical parameters showed 
that the higher administered dose of citral had comparable 
effect on many parameters—including enzyme liver and 
cytokines. Although it had a lower effect on some of the 
lipid profile indicators, it acted better on HDL, weight, 
and HOMA index.
PPARα is a transcriptional factor activated by 
ligands and can regulate the expression of genes involved 
in lipid oxidation pathway. Examples include genes of 
carnitine palmitoyl transferase 1. This has a role in fatty 
acids transporting into mitochondria and lipoprotein lipase, 
which is related to VLDL triglyceride lipolysis (Ziamajidi 
et al., 2013). Overall, PPARα has an important role in 
fatty acid oxidation, oxidative stress, energy balance, and 
lipid metabolism. In fact, a decrease in the expression of 
PPARα causes impaired fatty acids β-oxidation. This may 
result in imbalance of lipid metabolism and lead to lipid 
accumulation in the case of induced lipogenic transcription 
(Reddy, 2001). Our results show, in accordance to other 
studies, a marked decrease in PPARα over high-fat (HF) 
intake (Feige et al., 2006). Previous reports indicated 
that citral could activate PPARα expression by inducing 
mRNA expression of the PPARα responsive carnitine 
palmitoyltransferase 1 gene (Katsukawa et al., 2010). 
Accordingly, we observed that a 20mg/kg dose of citral 
considerably increased PPARα gene expression, as 
compared with the HF and Sham group.
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Hepatocytes and kupffer cells secrete TNF-α 
directly in the liver, while abdominal fat can also produce 
it. Several studies reported that TNF-α played a key role 
in developing NAFLD in human and animals. TNF-α is 
associated with insulin resistance and animals studies 
showed that the inhibition of TNF-alpha improved 
NAFLD (Chu et al., 2006). Similar to previous studies, we 
observed that high-fat emulsion treatment for four weeks 
significantly increased TNF-α levels in the HF group. On 
the other hand, citral treatment caused reduction in TNF-α 
levels. Citral can reportedLy inhibit inflammatory factors 
TNF-α and nitric oxide (NO) production. NF-κB, as a 
transcription factor, was a target for this anti-inflammatory 
effect and could be affected by citral (Song et al., 2016).
Finally, histopathological assessment of liver 
section revealed that treatment with citral caused a dose-
dependent decrease of steatosis and fibrosis. Overall, 
citral, especially at a dose of 20mg/kg, prevented lipid 
deposition (Figure 2M). On the other hand, Masson’s 
trichorome staining showed that citral at this dose had 
counteracted liver fibrosis. Liver fibrosis (marked with 
arrows in Figure 2D) was eliminated by citral 20mg/kg 
administration (Figure 2N).
Based on the above results, we suggested that citral 
could modify NAFLD through improved activity of anti-
oxidant enzymes, inhibition of inflammatory cytokine, and 
an increase of PPAR α gene expression. The overall effect 
of citral was comparable to silymarin, with better effect 
on some parameters. Due to the limited options available 
for NAFLD treatment and the need for a greater body of 
data on potentially effective compounds, citral could be 
proposed as an additional possibility in this regard.
CONCLUSION
Our results indicated that the administration of citral 
could control the harmful effects of NAFLD disease. 
This effect was exerted by up regulation of adiponectin, 
reduction of serum leptin levels, modulation of lipid 
profile, and increase of anti-oxidant enzyme levels. The 
effects of citral were notable and further development of 
this compound could potentially result into an effective 
therapeutic improvement of NAFLD.
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